



## **Aduro Biotech to Present at Three Investor Conferences in the First Half of September**

August 31, 2017

BERKELEY, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Aduro management will present at the following investor conferences in New York, NY the first half of September 2017:

- 2017 Baird Global Healthcare Conference on Thursday, September 7, 2017 at 7:55 am Eastern Time
- 24<sup>th</sup> Annual BioCentury NewsMakers Conference on Friday, September 8, 2017 at 8:30 am Eastern Time
- 18<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference on Monday, September 11, 2017 at 11:15 am Eastern Time

To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit Aduro's website at [www.aduro.com](http://www.aduro.com).

### **About Aduro**

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of *Listeria* that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, gastric, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient's tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro's B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and preclinical development, including BION-1301, an anti-APRIL antibody. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit [www.aduro.com](http://www.aduro.com).

#### Contact:

Sylvia Wheeler  
SVP, Corporate Affairs  
510 809 9264

#### Media Contact:

Susan Lehner  
510 809 2137  
[press@aduro.com](mailto:press@aduro.com)



Aduro Biotech, Inc.